X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2629) 2629
Publication (298) 298
Book Review (12) 12
Book Chapter (8) 8
Conference Proceeding (4) 4
Dissertation (2) 2
Data Set (1) 1
Magazine Article (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2532) 2532
erlotinib hydrochloride (1914) 1914
index medicus (1689) 1689
lung neoplasms - drug therapy (1532) 1532
oncology (1491) 1491
quinazolines - therapeutic use (1443) 1443
female (1376) 1376
erlotinib (1316) 1316
carcinoma, non-small-cell lung - drug therapy (1300) 1300
male (1226) 1226
middle aged (1101) 1101
protein kinase inhibitors - therapeutic use (1066) 1066
aged (1015) 1015
antineoplastic agents - therapeutic use (933) 933
receptor, epidermal growth factor - antagonists & inhibitors (911) 911
gefitinib (885) 885
chemotherapy (751) 751
adult (713) 713
antineoplastic combined chemotherapy protocols - therapeutic use (706) 706
lung neoplasms - pathology (702) 702
treatment outcome (675) 675
mutation (662) 662
receptor, epidermal growth factor - genetics (649) 649
lung neoplasms - genetics (632) 632
cancer (590) 590
quinazolines - administration & dosage (580) 580
carcinoma, non-small-cell lung - pathology (509) 509
carcinoma, non-small-cell lung - genetics (489) 489
aged, 80 and over (484) 484
lung cancer (472) 472
lung cancer, non-small cell (442) 442
quinazolines - adverse effects (439) 439
epidermal growth factor (420) 420
care and treatment (405) 405
growth-factor receptor (404) 404
erlotinib hydrochloride - therapeutic use (396) 396
cell lung-cancer (388) 388
egfr (382) 382
disease-free survival (381) 381
adenocarcinoma - drug therapy (380) 380
respiratory system (340) 340
animals (331) 331
neoplasm staging (324) 324
tyrosine kinase inhibitor (322) 322
lung neoplasms - mortality (317) 317
quinazolines - pharmacology (314) 314
therapy (306) 306
non-small cell lung cancer (303) 303
cell line, tumor (297) 297
receptor, epidermal growth factor - metabolism (295) 295
carcinoma, non-small-cell lung - mortality (293) 293
prognosis (288) 288
respiratory tract diseases (285) 285
open-label (275) 275
hematology, oncology and palliative medicine (272) 272
survival (269) 269
antibodies, monoclonal, humanized (268) 268
bevacizumab (255) 255
epidermal growth factor receptor (253) 253
cetuximab (252) 252
research (252) 252
mutations (248) 248
protein kinase inhibitors - adverse effects (246) 246
adenocarcinoma (245) 245
deoxycytidine - analogs & derivatives (238) 238
survival rate (230) 230
phase-iii trial (228) 228
trial (228) 228
pharmacology & pharmacy (225) 225
antibodies, monoclonal - therapeutic use (223) 223
antineoplastic agents - pharmacology (221) 221
retrospective studies (221) 221
tyrosine (221) 221
tyrosine kinase inhibitors (219) 219
acquired-resistance (217) 217
tumors (216) 216
1st-line treatment (212) 212
mice (210) 210
protein kinase inhibitors - pharmacology (210) 210
analysis (209) 209
antineoplastic agents - adverse effects (209) 209
article (203) 203
expression (198) 198
pancreatic neoplasms - drug therapy (195) 195
gemcitabine (194) 194
antineoplastic combined chemotherapy protocols - adverse effects (192) 192
disease progression (189) 189
drug therapy (189) 189
erlotinib hydrochloride - administration & dosage (188) 188
deoxycytidine - administration & dosage (185) 185
nsclc (183) 183
protein kinase inhibitors - administration & dosage (183) 183
pulmonary/respiratory (182) 182
survival analysis (181) 181
adenocarcinoma - pathology (180) 180
multicenter (178) 178
adenocarcinoma - genetics (176) 176
combination (174) 174
health aspects (174) 174
metastasis (173) 173
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2448) 2448
French (49) 49
Japanese (39) 39
Chinese (36) 36
German (25) 25
Czech (8) 8
Spanish (8) 8
Hungarian (7) 7
Dutch (4) 4
Danish (2) 2
Korean (2) 2
Norwegian (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Polish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Wu, Yi-Long and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of Oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
by Zhou, Caicun and Wu, Y.L and Chen, G and Feng, J and Liu, X.-Q and Wang, C and Zhang, S and Wang, J and Zhou, S and Ren, S and Lu, S and Zhang, L and Hu, C and Hu, C and Luo, Y and Chen, L and Ye, M and Huang, J and Zhi, X and Zhang, Y and Xiu, Q and Ma, J and Zhang, L and You, C
Annals of Oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1877 - 1883
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4, pp. 412 - 420
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 10, pp. 1070 - 1077
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | CLATHRIN-MEDIATED ENDOCYTOSIS | CELLS | DRUG-DELIVERY | CHITOSAN | TUMOR | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | PACLITAXEL | NANOPARTICLES | ENHANCED PERMEABILITY | CANCER-TREATMENT | PHARMACOLOGY & PHARMACY | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3248 - 3257
Journal Article
by Schuler, Martin and Yang, J.C.-H and Park, K and Kim, J.-H and Bennouna, Jaafar and Chen, Y.-M and Chouaid, C and De Marinis, F and Feng, J.-F and Grossi, Francesco and Kim, D.-W and Liu, X and Lu, S and Strausz, J and Vinnyk, Y and Wiewrodt, R and Zhou, C and Wang, B and Chand, V.K and Planchard, D and Bagnes, Claudia and Martin, Claudio Marcelo and Recondo, Gonzalo and Zarba, Juan Jose and Blajman, Cesar and Richardet, Martín and McLachlan, Sue-Anne and Parente, Phillip and Underhill, Craig and Crombie, Catherine and Mainwaring, Paul and Greil, Richard and Humblet, Yves and Bustin, Frédérique and Carestia, Luciano and Galdermans, Danny and Lambrechts, Marc and Delval, Laetitia and Vercauter, Piet and Zhou, Caicun and Wang, Jin and Huang, Cheng and Lin, Xiaoyan and Wu, Yilong and Liu, Xiaoqing and Cheng, Ying and Qin, Shukui and Feng, Jifeng and Huang, Jianjin and Zhang, Yiping and Lu, Shun and Zereu, Manuela and Garicochea, Bernardo and Zadra, Cyntia Albuquerque and Riska, Henrik and Alanko, Tuomo and Cadranel, Jacques and Chouaid, Christos and Zalcman, Gérard and Sibilot, Denis Moro and Perol, Maurice and Planchard, David and Bennouna, Jaafar and Fournel, Pierre and Gervais, Radj and Rotarski, Maciej and Coudert, Bruno and Thomas, Michael and Wehler, Thomas and Faehling, Martin and Keilholz, Ulrich and Laack, Eckart and Von Pawel, Joachim and Huber, Rudolf and Dickgreber, Nicolas and Wiewrodt, Rainer and Mark, Zsuzsanna and Tehenes, Sandor and Strausz, Janos and Sarosi, Veronika and Prabhash, Kumar and Jain, Minish and Venkatesan, Srinivasan and Sharma, Lalit and Dadhich, Hemant and Nagarkar, Rajnish Vasant and Onn, Amir and Gottfried, Maya and Stemmer, Solomon and Migliorino, Maria Rita and Bidoli, Paolo and Bearz, Alessandra and Gridelli, Cesare and Milandri, Carlo and Platania, Marco and Ceresoli, Giovanni Luca and Cruciani, Giorgio and Delgado, Francisco Gutierrez and Perez, José Luis Gonzalez and Luna, Gabriela Alvarado and ... and Lux-Lung 5 Investigators and LUX-Lung 5 Investigators
Annals of Oncology, ISSN 0923-7534, 03/2016, Volume 27, Issue 3, pp. 417 - 423
Journal Article